WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, May 11, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC; PLUR=YES; OP=OR		
☐	L4	(cyclic with (protein or peptide or polypeptide)).clm. and L3	3
☐	L3	(disaccharide or polysaccharide or (sodium adj chloride) or maltose or lactose or sucrose) and L2	12
☐	L2	L1 and lyophili$.clm.	15
☐	L1	(514/9)[CCLS]	996

END OF SEARCH HISTORY

10/772,281

```
FILE 'HOME' ENTERED AT 11:17:31 ON 11 MAY 2006

=> b reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:18:20 ON 11 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 MAY 2006  HIGHEST RN 883788-13-4
DICTIONARY FILE UPDATES:  10 MAY 2006  HIGHEST RN 883788-13-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10772281.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 11:19:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      144 TO ITERATE

100.0% PROCESSED      144 ITERATIONS                          45 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2161 TO     3599
PROJECTED ANSWERS:             498 TO     1302

L2           45 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:19:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2957 TO ITERATE

100.0% PROCESSED     2957 ITERATIONS                        1003 ANSWERS
SEARCH TIME: 00.00.01

L3         1003 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10772281one.str

L4      STRUCTURE UPLOADED

=> s l4
SAMPLE SEARCH INITIATED 11:22:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1733 TO ITERATE

100.0% PROCESSED     1733 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        32163 TO    37157
PROJECTED ANSWERS:            1674 TO     2966

L5           50 SEA SSS SAM L4

=> s l4 full sub=l3
FULL SUBSET SEARCH INITIATED 11:23:08 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      881 TO ITERATE

100.0% PROCESSED      881 ITERATIONS                         881 ANSWERS
SEARCH TIME: 00.00.01

L6          881 SEA SUB=L3 SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\10772281two.str

L7      STRUCTURE UPLOADED

=> s l7
SAMPLE SEARCH INITIATED 11:27:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       79 TO ITERATE

100.0% PROCESSED       79 ITERATIONS                           0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1047 TO     2113
PROJECTED ANSWERS:               0 TO        0

L8            0 SEA SSS SAM L7

=> s l7 full
FULL SEARCH INITIATED 11:27:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1550 TO ITERATE

100.0% PROCESSED     1550 ITERATIONS                           9 ANSWERS
SEARCH TIME: 00.00.01

L9            9 SEA SSS FUL L7
```

```
=> d his

     (FILE 'HOME' ENTERED AT 11:17:31 ON 11 MAY 2006)

     FILE 'REGISTRY' ENTERED AT 11:18:20 ON 11 MAY 2006
L1             STRUCTURE UPLOADED
L2              45 S L1
L3            1003 S L1 FULL
L4             STRUCTURE UPLOADED
L5              50 S L4
L6             881 S L4 FULL  SUB=L3
L7             STRUCTURE UPLOADED
L8               0 S L7
L9               9 S L7 FULL

=> b caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             379.88     380.09

FILE 'CAPLUS' ENTERED AT 11:28:39 ON 11 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 11 May 2006  VOL 144 ISS 20
FILE LAST UPDATED: 10 May 2006  (20060510/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l9
L10          13 L9

=> d l10 1-13 ti ed

L10  ANSWER 1 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   New process for preparation of isoxazole derivative
ED   Entered STN:  22 Feb 2004

L10  ANSWER 2 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of cyclic peptides having antimicrobial activity
ED   Entered STN:  20 Sep 2002

L10  ANSWER 3 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Echinocandin derivatives, pharmaceutical compositions containing same and
     use thereof as drugs
ED   Entered STN:  08 Sep 2002

L10  ANSWER 4 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Streptomyces cyclic lipopeptide acylase genes, recombinant expression, and
     use for deacylation of cyclic lipopeptides
ED   Entered STN:  12 Jan 2001

L10  ANSWER 5 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of cyclic hexapeptides having antibiotic activity
ED   Entered STN:  03 Nov 2000

L10  ANSWER 6 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Cyclic hexapeptides having antimicrobial activity
ED   Entered STN:  18 Aug 1999

L10  ANSWER 7 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   FK463, a novel water-soluble echinocandin lipopeptide: synthesis and
     antifungal activity
ED   Entered STN:  10 Aug 1999

L10  ANSWER 8 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Cyclohexapeptides having antimicrobial activity
ED   Entered STN:  25 Jun 1998

L10  ANSWER 9 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Cyclic hexapeptides having antibiotic activity
ED   Entered STN:  06 Aug 1996

L10  ANSWER 10 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of cyclic peptide compounds as β-1,3-glucan synthase
     inhibitors and antimicrobial agents
ED   Entered STN:  30 Aug 1995

L10  ANSWER 11 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of cyclic peptide derivatives as antibacterial agents
ED   Entered STN:  02 Apr 1994

L10  ANSWER 12 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Pharmaceutical composition against Pneumocystis carinii
ED   Entered STN:  29 May 1993

L10  ANSWER 13 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of cyclic peptide (echinocandin B) antibiotics
ED   Entered STN:  08 Aug 1992


=> s l10 and lyoph?
         22130 LYOPH?
L11          1 L10 AND LYOPH?

=> d l11

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   1995:763519  CAPLUS
DN   123:228903
TI   Preparation of cyclic peptide compounds as β-1,3-glucan synthase
     inhibitors and antimicrobial agents
IN   Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
PA   Fujisawa Pharmaceutical Co., Ltd., Japan
SO   Can. Pat. Appl., 85 pp.
     CODEN: CPXXEB
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   CA 2123921          AA     19941118    CA 1994-2123921         19940517
     AU 9461994          A1     19941124    AU 1994-61994           19940510
     AU 681119           B2     19970821
     IL 109615           A1     20001206    IL 1994-109615          19940510
     EP 644199           A1     19950322    EP 1994-107406          19940512
     EP 644199           B1     20000719
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     AT 194846           E      20000815    AT 1994-107406          19940512
     ES 2148254          T3     20001016    ES 1994-107406          19940512
     PT 644199           T      20010131    PT 1994-107406          19940512
     CN 1100104          A      19950315    CN 1994-105193          19940516
```

```
     CN 1057306           B     20001011
     ZA 9403356           A     19950328    ZA 1994-3356          19940516
     HU 68385             A2    19950628    HU 1994-1515          19940516
     US 5569646           A     19961029    US 1994-242854        19940516
     RU 2164230           C2    20010320    RU 1994-16354         19940516
     JP 06340693          A2    19941213    JP 1994-126977        19940517
     JP 3551469           B2    20040804
     US 5693750           A     19971202    US 1996-675212        19960703
     GR 3034366           T3    20001229    GR 2000-402052        20000908
PRAI GB 1993-10091        A     19930517
     GB 1993-25269        A     19931210
     US 1994-242854       A3    19940516
OS   MARPAT 123:228903

=> s l11 and sodium chloride
       1034606 SODIUM
            34 SODIUMS
       1034615 SODIUM
                  (SODIUM OR SODIUMS)
       1074646 CHLORIDE
        156910 CHLORIDES
       1146501 CHLORIDE
                  (CHLORIDE OR CHLORIDES)
        124486 SODIUM CHLORIDE
                  (SODIUM(W)CHLORIDE)
L12           0 L11 AND SODIUM CHLORIDE

=> s l11 and disaccharide
         11400 DISACCHARIDE
          9804 DISACCHARIDES
         17555 DISACCHARIDE
                  (DISACCHARIDE OR DISACCHARIDES)
L13           0 L11 AND DISACCHARIDE

=> s l11 and polysaccharide
         57554 POLYSACCHARIDE
         71881 POLYSACCHARIDES
         90858 POLYSACCHARIDE
                  (POLYSACCHARIDE OR POLYSACCHARIDES)
L14           0 L11 AND POLYSACCHARIDE

=> s l11 and maltose
         27025 MALTOSE
            40 MALTOSES
         27031 MALTOSE
                  (MALTOSE OR MALTOSES)
L15           0 L11 AND MALTOSE

=> s l11 and sucrose
        142073 SUCROSE
            93 SUCROSES
        142084 SUCROSE
                  (SUCROSE OR SUCROSES)
L16           0 L11 AND SUCROSE

=> s l11 and lactose
         50104 LACTOSE
            93 LACTOSES
         50112 LACTOSE
                  (LACTOSE OR LACTOSES)
L17           0 L11 AND LACTOSE

=> d his

     (FILE 'HOME' ENTERED AT 11:17:31 ON 11 MAY 2006)

     FILE 'REGISTRY' ENTERED AT 11:18:20 ON 11 MAY 2006
L1               STRUCTURE UPLOADED
L2            45 S L1
L3          1003 S L1 FULL
L4               STRUCTURE UPLOADED
L5            50 S L4
L6           881 S L4 FULL  SUB=L3
L7               STRUCTURE UPLOADED
L8             0 S L7
L9             9 S L7 FULL

     FILE 'CAPLUS' ENTERED AT 11:28:39 ON 11 MAY 2006
L10           13 S L9
L11            1 S L10 AND LYOPH?
L12            0 S L11 AND SODIUM CHLORIDE
L13            0 S L11 AND DISACCHARIDE
L14            0 S L11 AND POLYSACCHARIDE
L15            0 S L11 AND MALTOSE
L16            0 S L11 AND SUCROSE
L17            0 S L11 AND LACTOSE

=> s l6
L18          182 L6

=> s l18 and (disaccharide or polysaccharide or sodium chloride or maltose or sucrose or lactose)
         11400 DISACCHARIDE
          9804 DISACCHARIDES
         17555 DISACCHARIDE
                  (DISACCHARIDE OR DISACCHARIDES)
         57554 POLYSACCHARIDE
         71881 POLYSACCHARIDES
         90858 POLYSACCHARIDE
                  (POLYSACCHARIDE OR POLYSACCHARIDES)
       1034606 SODIUM
            34 SODIUMS
       1034615 SODIUM
                  (SODIUM OR SODIUMS)
       1074646 CHLORIDE
        156910 CHLORIDES
       1146501 CHLORIDE
                  (CHLORIDE OR CHLORIDES)
        124486 SODIUM CHLORIDE
                  (SODIUM(W)CHLORIDE)
         27025 MALTOSE
            40 MALTOSES
         27031 MALTOSE
                  (MALTOSE OR MALTOSES)
        142073 SUCROSE
            93 SUCROSES
        142084 SUCROSE
                  (SUCROSE OR SUCROSES)
         50104 LACTOSE
            93 LACTOSES
         50112 LACTOSE
                  (LACTOSE OR LACTOSES)
L19           4 L18 AND (DISACCHARIDE OR POLYSACCHARIDE OR SODIUM CHLORIDE OR
                MALTOSE OR SUCROSE OR LACTOSE)

=> d l19 1-4 bib abs

L19  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:612064  CAPLUS
DN   143:139157
TI   Preparation of rigid liposomal cochleate
IN   Krause-Elsmore, Sara L.; Mannino, Raphael J.
PA   Biodelivery Sciences International, Inc., USA
SO   PCT Int. Appl., 50 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063213	A1	20050714	WO 2004-US42927	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-531546P	P	20031219		
	US 2004-565120P	P	20040423		

AB Employing liposomes having a high transition temperature at least partially disposed in a matrix, compns. are provided that can be used to deliver one or more cargo moieties, e.g., a drug, a nutrient, an imaging agent and/or nonsteroidal anti-inflammatory drug. The matrix can be a lipid precipitate and/or a cationic bridge. Methods of making and using these compns. preferably cochleates, are also disclosed. Rigid liposomes were obtained from distearoylphosphatidylserine and dextran.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:902155 CAPLUS
DN 141:384286
TI Novel encochleation methods, cochleates and methods of use
IN Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.; Delmarre, David; Lu, Ruying
PA Biodelivery Sciences International, Inc., USA; University of Medicine and Dentistry of New Jersey
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091578	A2	20041028	WO 2004-US11026	20040409
	WO 2004091578	C1	20050127		
	WO 2004091578	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005013854	A1	20050120	US 2004-822230	20040409
	EP 1624858	A2	20060215	EP 2004-759375	20040409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-461483P	P	20030409		
	US 2003-463076P	P	20030415		
	US 2003-499247P	P	20030828		
	US 2003-502557P	P	20030911		
	US 2003-532755P	P	20031224		
	US 2004-537252P	P	20040115		
	US 2004-556192P	P	20040324		
	WO 2004-US11026	W	20040409		

AB The invention generally relates to cochleate drug delivery vehicles. Disclose are novel methods for making cochleates and cochleate compns. that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compns. that include an aggregation inhibitor, and optionally, a cargo moiety. Addnl., anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a neg. charge lipid are disclosed. Methods of using the cochleate compns. of the invention, including methods of administration, are also disclosed.

L19 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:757023 CAPLUS
DN 139:281230
TI Bioadhesive vaginal drug delivery system containing an acidic buffer
IN Kirschner, Mitchell I.; Levinson, R. Saul; Riley, Thomas C.; Hermelin, Marc S.
PA KV Pharmaceutical Company, USA
SO U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003180366	A1	20030925	US 2002-101014	20020320
	US 6899890	B2	20050531		
	CA 2392473	AA	20030920	CA 2002-2392473	20020628
	AU 2002300175	A1	20031009	AU 2002-300175	20020715
	BR 2002002767	A	20040525	BR 2002-2767	20020718
	CN 1444926	A	20031001	CN 2002-127087	20020729
	JP 2003286193	A2	20031007	JP 2002-266381	20020912
	PT 102854	A	20030930	PT 2002-102854	20021015
	PT 102854	B	20040227		
	FR 2837389	A1	20030926	FR 2002-14858	20021127
	WO 2003079981	A2	20031002	WO 2003-US8266	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003218233	A1	20031008	AU 2003-218233	20030319
PRAI	US 2002-101014	A	20020320		
	WO 2003-US8266	W	20030319		

AB The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insol. phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase. For example, a vaginal drug delivery system was prepared containing metronidazole 0.75%, water 24.676%, glycerin 47.25%, acetic acid 0.225%, sodium acetate 0.20%, **sodium chloride** 0.75%, methylparaben 0.09%, propylparaben 0.035%, butylparaben 0.024%, **sucrose** 8.0%, mineral oil 13.0%, and polyethylene glycol (30) dipolyhydroxystearate 5.0%.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31345 CAPLUS
DN 134:105851
TI Stabilized cyclic polypeptide pharmaceutical composition in lyophilized form
IN Sawai, Seiji; Kasai, Akihiro; Otomo, Kazumi

PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002002	A1	20010111	WO 2000-JP4381	20000629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341568	AA	20010111	CA 2000-2341568	20000629
AU 2000055722	A5	20010122	AU 2000-55722	20000629
AU 752265	B2	20020912		
BR 2000006823	A	20010605	BR 2000-6823	20000629
EP 1107777	A1	20010620	EP 2000-940916	20000629
EP 1107777	B1	20041027		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100609	T1	20010723	TR 2001-200100609	20000629
JP 2002363097	A2	20021218	JP 2001-312701	20000629
JP 2003503462	T2	20030128	JP 2001-507492	20000629
JP 3381722	B2	20030304		
NZ 510290	A	20030725	NZ 2000-510290	20000629
AT 280583	E	20041115	AT 2000-940916	20000629
PT 1107777	T	20050131	PT 2000-940916	20000629
ES 2225161	T3	20050316	ES 2000-940916	20000629
RU 2251411	C2	20050510	RU 2001-108569	20000629
CN 1636591	A	20050713	CN 2004-10088076	20000629
CZ 295720	B6	20051012	CZ 2001-1186	20000629
NO 2001000893	A	20010424	NO 2001-893	20010222
ZA 2001001589	A	20020902	ZA 2001-1589	20010226
US 6774104	B1	20040810	US 2001-786125	20010301
HK 1040057	A1	20050805	HK 2002-101689	20020305
US 2004157769	A1	20040812	US 2004-772281	20040206
PRAI JP 1999-187713	A	19990701		
JP 2001-507492	A3	20000629		
WO 2000-JP4381	W	20000629		
US 2001-786125	A3	20010301		

OS MARPAT 134:105851
AB A stabilized pharmaceutical composition in lyophilized form comprises a cyclic polypeptide and one or more stabilizer(s) selected from the group consisting of a **polysaccharide**, a **disaccharide** and **sodium chloride**. A composition was prepared containing a cyclic polypeptide and **lactose**.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:17:31 ON 11 MAY 2006)

FILE 'REGISTRY' ENTERED AT 11:18:20 ON 11 MAY 2006
L1 STRUCTURE UPLOADED
L2 45 S L1
L3 1003 S L1 FULL
L4 STRUCTURE UPLOADED
L5 50 S L4
L6 881 S L4 FULL SUB=L3
L7 STRUCTURE UPLOADED
L8 0 S L7
L9 9 S L7 FULL

FILE 'CAPLUS' ENTERED AT 11:28:39 ON 11 MAY 2006
L10 13 S L9
L11 1 S L10 AND LYOPH?
L12 0 S L11 AND SODIUM CHLORIDE
L13 0 S L11 AND DISACCHARIDE
L14 0 S L11 AND POLYSACCHARIDE
L15 0 S L11 AND MALTOSE
L16 0 S L11 AND SUCROSE
L17 0 S L11 AND LACTOSE
L18 182 S L6
L19 4 S L18 AND (DISACCHARIDE OR POLYSACCHARIDE OR SODIUM CHLORIDE OR

C:\Program Files\Stnexp\Queries\10772281two.str





chain nodes :
7 8 14 15 16 17 24 34 35 36 44 45 46 47 48 49 50 51 52 53 54 55 56
58 59 61 62 63 64 65
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 18 19 20 21 22 23 25 26 27 28 29 30 31 32
33 37 38 39 40 41 42 43
chain bonds :
2-44 3-62 5-7 7-8 7-58 8-9 8-45 10-50 13-14 14-15 14-46 15-16 16-17 16-51
18-52 21-47 22-24 25-53 27-59 28-48 30-61 31-54 33-34 34-35 34-36 37-55 40-49
43-56 62-63 63-64 64-65
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-11 11-13 12-43 13-18 18-19 19-20 19-23
20-21 20-25 21-22 22-23 25-26 26-27 27-28 28-29 29-30 30-31 31-32 32-33 33-37
37-38 38-39 38-42 39-40 40-41 41-42 42-43
exact/norm bonds :
2-44 3-62 7-58 8-45 9-10 9-12 10-11 10-50 11-13 12-43 13-18 14-46 16-17 16-51
18-19 18-52 19-20 19-23 20-21 20-25 21-22 21-47 22-23 25-26 25-53 26-27 27-28
27-59 28-29 28-48 29-30 30-31 30-61 31-32 31-54 32-33 33-37 34-35 37-38 37-55
38-39 38-42 39-40 40-41 40-49 41-42 42-43 43-56 62-63 63-64
exact bonds :
5-7 7-8 8-9 13-14 14-15 15-16 22-24 33-34 34-36 64-65
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:OH,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS 36:CLASS 37:Atom 38:Atom 39:Atom 40:Atom
41:Atom

42:Atom 43:Atom 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 58:CLASS 59:CLASS
61:CLASS 62:CLASS 63:CLASS 64:CLASS 65:CLASS

C:\Program Files\Stnexp\Queries\10772281one.str





chain nodes :
7 8 9
ring nodes :
1 2 3 4 5 6
chain bonds :
2-7 3-8 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-7 3-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS

C:\Program Files\Stnexp\Queries\10772281.str





chain nodes :
7 8 14 15 16 17 24 34 35 36 44 45 46 47 48 49 50 51 52 53 54 55 56
58 59 61
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 18 19 20 21 22 23 25 26 27 28 29 30 31 32
33 37 38 39 40 41 42 43
chain bonds :
2-44 5-7 7-8 7-58 8-9 8-45 10-50 13-14 14-15 14-46 15-16 16-17 16-51 18-52
21-47 22-24 25-53 27-59 28-48 30-61 31-54 33-34 34-35 34-36 37-55 40-49 43-56
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-11 11-13 12-43 13-18 18-19 19-20 19-23
20-21 20-25 21-22 22-23 25-26 26-27 27-28 28-29 29-30 30-31 31-32 32-33 33-37
37-38 38-39 38-42 39-40 40-41 41-42 42-43
exact/norm bonds :
2-44 7-58 8-45 9-10 9-12 10-11 10-50 11-13 12-43 13-18 14-46 16-17 16-51 18-19
18-52 19-20 19-23 20-21 20-25 21-22 21-47 22-23 25-26 25-53 26-27 27-28 27-59
28-29 28-48 29-30 30-31 30-61 31-32 31-54 32-33 33-37 34-35 37-38 37-55 38-39
38-42 39-40 40-41 40-49 41-42 42-43 43-56
exact bonds :
5-7 7-8 8-9 13-14 14-15 15-16 22-24 33-34 34-36
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:OH,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS 36:CLASS 37:Atom 38:Atom 39:Atom 40:Atom
41:Atom 42:Atom 43:Atom 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS
50:CLASS

51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 58:CLASS 59:CLASS
61:CLASS